The new gefitinib cancer-treating drug, whose Chinese commercial name is Yiruike, was produced by Qilu Pharmaceutical . Its release ends an almost decade-long monopoly by Iressa, developed by British multinational biopharmaceutical company AstraZeneca and introduced to China in 2005.